Users Group Meeting 2007 for PDS Pathology Data Systems' PathData, ToxData and ReproData Systems Concludes with Exciting News

Share Article

Preclinical Software provider PDS Pathology Data Systems Ltd , developer of the PathData, ToxData and ReproData Systems, recently concluded its Users Group Meeting in Basel, Switzerland by welcoming its seventeen new pharmaceutical, biotech and CRO companies to the growing family of users representing all areas of the preclinical spectrum.

Almost one hundred PathData, ToxData and ReproData System users from all over the world attended the recent PDS Users Group Meeting held in Basel, Switzerland.

With the prior Users Group Meeting just eighteen months earlier, a stunned audience was introduced to the seventeen newest customers to join the PDS family of users since then. Newest Users include global pharmaceutical companies, CROs and biotechs that are pleased to now be working with a vendor that truly can meet and exceed their needs.

Highlights of the meeting included presentations by users themselves, including Teva DRI, the leading generica company worldwide and one of the User Group's newest members, pharmaceutical industry leader Pfizer.

Pfizer representatives explained how they leveraged an innovative vendor selection process with an aggressive time line to not only give them great confidence in their vendor selection, but to assure their ability to roll out mission-critical software across multiple sites within the planned project parameters using a collaborative approach with their vendor partners.

The extraordinary value of utilizing the FDA's risk-based approach for validation was presented by Teva DRI representatives. Teva demonstrated how a thorough validation of the PDS software was performed on an expedited basis following the FDA guidelines. They were able to achieve significant savings in time and resources while still maintaining the highest quality and utmost confidence in their results.

A portion of the two-day meeting included highlights of the newest features contained in the most recent releases of the integrated product suite of PathData, ToxData and ReproData. An early peek at the next major upcoming release of PathData was also provided and it included insights into several exciting industry-first innovations that encompass beyond-the-horizon tools for the pathology community that have never been available anywhere before.

The Users Group was provided a behind-the-scenes look at how the ASP Subscription Model for software deployment functions and why it is the most trusted and most widely used software service for preclinical studies. The same world-class software that is licensed in a traditional way can also be licensed through a Subscription option, allowing a customer to simply pay as they go with no up-front capital expense and no additional IT burden. Unlike other Application Service Provider (ASP) solutions for preclinical studies, the PDS Subscription Service is the only one to literally be GLP-Certified, making the validation of the system by the user far simpler than any other alternative in the preclinical marketplace.

About PDS Pathology Data Systems, Ltd
PDS (http://www.pds-america.com) has a twenty-eight year history of providing preclinical software solutions to a very well-satisfied user base. With worldwide headquarters in Basel, Switzerland and New Jersey offices for North America sales and support, PDS provides a full product suite of software solutions through its integrated and modular systems: PathData for post mortem activities, ToxData for general toxicology and clinical pathology and ReproData for reproductive and teratology studies.

PDS software is used by seven of the top ten pharmaceutical companies in the world and a user base from North America, Europe, China and Japan of small working groups to global multi-site organizations. Because it is a very flexible and multilingual system that is not dependent on any third-party applications, the PDS Software Suite it is ideally suited for a wide variety of users.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Arthur Karakos, CEO
Visit website